Hasegawa S, Tanaka T, Saito T, Fukui K, et al. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney Int 2019 Dec 25. pii: S0085-2538(19)31247.
PMID: 32171449